Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia.

@article{Hilton2009MutationalIO,
  title={Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia.},
  author={Douglas J. Hilton and Benjamin T Kile and Warren S. Alexander},
  journal={Blood},
  year={2009},
  volume={113 22},
  pages={
          5599-604
        }
}
The transcription factor c-Myb and coregulator p300 have a key role in maintaining production of controlled numbers of megakaryocytes and platelets. In mice, mutations in c-Myb or p300 cause thrombocytosis in otherwise wild-type animals and can ameliorate the thrombocytopenia in mice lacking the thrombopoietin receptor, c-Mpl, a model for human congenital amegakaryocytic thrombocytopenia. To examine whether inhibition of c-Myb/p300 is effective in other models of thrombocytopenia, the effect of… CONTINUE READING